CHECKLIST for Nurses and EMS Personnel
Administering MODERNA COVID-19 VACCINE Under EUA
GMVEMSC JITSO for Paramedics and Adv. EMTs 12/22/2020

Moderna COVID Vaccine is a suspension for intramuscular (IM) injection

For Storage and other handling information, see the full "EUA Fact Sheet for Providers"

The storage and handling information in the EUA Fact Sheet supersede storage and handling information on the vial and carton labels.





Dose Preparation: 5 key points when preparing to administer Moderna COVID-19 Vaccine:

1. Remove required number of vials from frozen storage and thaw each vial before use:

- The Moderna COVID-19 Vaccine multiple-dose vial contains a frozen suspension that does not contain a preservative and must be thawed prior to administration.
- Thaw in refrigerated conditions between 2° to 8°C (36° to 46°F) for 2 hours and 30 minutes. After thawing, let vial stand at room temperature for 15 minutes before administering.
- Alternatively, thaw at room temperature between 15° to 25°C (59° to 77°F) for 1 hour.
- After thawing, do not refreeze.

2. **Swirl vial gently after thawing and between each withdrawal. <u>DO NOT SHAKE.</u> Do not dilute the vaccine.**
3. Visually inspect Moderna COVID Vaccine. It is a white to off-white suspension. It may contain white or translucent product-related particulates. If there is other particulate matter and/or discoloration, the vaccine should not be administered.
4. Each dose is 0.5 mL.
5. After the first dose has been withdrawn, the vial should be held between 2° to 25°C (36° to 77°F). Record the date and time for first use on the Moderna COVID-19 Vaccine vial label. Discard vial after 6 hours. Do not refreeze.

Dosing and Schedule

- Individuals who have received one dose of the Moderna COVID-19 Vaccine should receive a **second dose of the <u>Moderna</u>** COVID- 19 **Vaccine** to complete the vaccination series.

Vaccine Administration

Administered intramuscularly as a series of two doses (0.5 mL each) 1 month apart.
Visually inspect each dose (as above):

- Verify the dosing volume of 0.5 mL.
- Confirm no other particulates and no discoloration is observed.
- Do not administer if vaccine is discolored or contains other particulate matter.

Provide a vaccination card to recipient or caregiver with date to return for the second dose.

IM Injections in Deltoid Muscle

- **Use proper landmarks and technique to identify the injection site**
- **Use proper needle length for age and size of patient**
- **Aspiration is not recommended when administering vaccines**



FIGURE 31.38 A method of establishing the deltoid muscle site for an intramuscular injection





Monitoring and Reporting Requirements

Moderna COVID-19 Vaccine is limited to the following (**all requirements must be met**):

1. For use in individuals 18 years of age and older.
2. Provide "Fact Sheet for Recipients and Caregivers" **prior** to giving the Vaccine.
3. Document in the state/local jurisdiction's Immunization Information System (IIS) or other designated system. Advise recipient or caregiver that more information about IISs can be found at: https://www.cdc.gov/vaccines/programs/iis/about.html.
4. The vaccination provider is responsible for mandatory reporting of the following to the Vaccine Adverse Event Reporting System (VAERS):
   - vaccine administration errors whether or not associated with an adverse event, serious adverse events* (irrespective of attribution to vaccination), cases of Multisystem Inflammatory Syndrome (MIS), and cases of COVID-19 that result in hospitalization or death.
   - Submit reports to VAERS online at https://vaers.hhs.gov/reportevent.html.

Contraindications

Do not administer the Moderna COVID-19 Vaccine to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19 Vaccine.

Warnings and Precautions

Appropriate treatment to manage immediate allergic reactions must be immediately available
Monitor Moderna COVID-19 vaccine recipients for the occurrence of immediate adverse reactions:

- **At least 15 minutes for all recipients**
- **At least 30 minutes for recipients with a prior history of allergic reactions**
- Media reports indicate there have been some syncopal episodes after the injection. These are likely vasovagal reactions to the injection; no indication of anything to do with the vaccine. Manage with positioning and supportive care.

Adverse Reactions

- Adverse reactions reported in a clinical trial following administration of the Moderna COVID-19 Vaccine include pain at the injection site, fatigue, headache, myalgia, arthralgia, chills, nausea/vomiting, axillary swelling/tenderness, fever, swelling at the injection site, and erythema at the injection site.
- Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Moderna COVID-19 Vaccine.

Provide the **v-safe** information sheet to vaccine recipients/caregivers and encourage vaccine recipients to participate in **v-safe**. **V-safe** is a new voluntary smartphone-based tool that uses text messaging and web surveys to check in with people who have been vaccinated to identify potential side effects after COVID-19 vaccination. **V-safe** asks questions that help CDC monitor the safety of COVID-19 vaccines. **V-safe** also provides second-dose reminders if needed and live telephone follow-up by CDC if participants report a significant health impact following COVID- 19 vaccination. For more information, visit: www.cdc.gov/vsafe.